Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.

ABSTRACT:

Objectives

To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period.

Methods

Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offered extended treatment with follow-up for an additional 2 years. During the extension phase, treatment with 25 mg rituximab was administered every 6 months via a subcutaneous Ommaya reservoir connected to the right frontal horn with a ventricular catheter.

Results

Mild to moderate vertigo and nausea occurred in 4 out of 14 participants as temporary adverse events associated with IT rituximab infusion. During the entire 3-year period, two cases of low-virulent bacterial meningit

SUBMITTER: Bergman J 

PROVIDER: S-EPMC7880973 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature